Michael Mauro, MD, is the leader of the Myeloproliferative Neoplasms Program at the Memorial Sloan Kettering Cancer Center. Before this Dr Mauro worked at the OHSU Knight Cancer Institute for 13 years, where he directed the chronic myeloid leukemia (CML) clinical trial program. He received his medical degree from Dartmouth Medical School in Hannover, NH. Following this, Dr Mauro completed a residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan, NY.
Speaking on chronic myeloid leukemia
Dr Mauro’s areas of expertise are predominantly myeloproliferative disorders, such as chronic myeloid leukemia, myelofibrosis, polycythemia vera, and thrombocytosis. His clinical focus is CML, with particular interests in optimizing therapy and managing side effects and intolerance to therapy. Dr Mauro has been the principal investigator of several clinical trials investigating novel therapies for patients with CML. In addition, he has been the co-investigator of multiple Phase I/II clinical trials for patents with myelofibrosis.